Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety, Antiviral Activity, and Pharmacokinetics of BI 207127 NA Administered in Combination With Peg-IFN and Ribavirin in Chronic HCV-infected Patients for 4 Weeks, a Randomised, Double-blind, Placebo Controlled Study
Brief Summary: The main purpose of this clinical trial with BI 207127 is to see the effect of 4 week combination of BI 207127 with Peginterferon alfa (Peg-IFN) and Ribavirin (RBV) on hepatitis C virus (HCV) virus load and how safe BI 207127 is in this combination in HCV infected patients.


Options:
A: Arm Label: Phase 2a: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: Peginterferon Alfa-2a, Drug: Ribavirin | Arm Label: Phase 2a: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon Alfa-2a, Drug: Ribavirin | Arm Label: Phase 2b: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BMS-650032, Drug: Placebo, Drug: Peginterferon Alfa-2a, Drug: Ribavirin | Arm Label: Phase 2b: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon Alfa-2a, Drug: Ribavirin | Intervention Type: DRUG; Name: BMS-650032; Assigned to Arm(s): Phase 2a: Arm 1 | Intervention Type: DRUG; Name: BMS-650032; Assigned to Arm(s): Phase 2b: Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Phase 2a: Arm 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Phase 2b: Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Phase 2b: Arm 2 | Intervention Type: DRUG; Name: Peginterferon Alfa-2a; Assigned to Arm(s): Phase 2a: Arm 1, Phase 2a: Arm 2, Phase 2b: Arm 2 | Intervention Type: DRUG; Name: Peginterferon Alfa-2a; Assigned to Arm(s): Phase 2b: Arm 1 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Phase 2a: Arm 1, Phase 2a: Arm 2, Phase 2b: Arm 2 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Phase 2b: Arm 1
B: Arm Label: BI 207127 low dose + SOC; Type: EXPERIMENTAL; Interventions: Drug: BI 207127 low dose + SOC | Arm Label: BI 207127 middle dose +SOC; Type: EXPERIMENTAL; Interventions: Drug: BI 207127 middle dose +SOC | Arm Label: BI 207127 high dose+SOC; Type: EXPERIMENTAL; Interventions: Drug: BI 207127 high dose+SOC | Arm Label: Placebo + SOC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + SOC | Intervention Type: DRUG; Name: BI 207127 middle dose +SOC; Assigned to Arm(s): BI 207127 middle dose +SOC | Intervention Type: DRUG; Name: BI 207127 high dose+SOC; Assigned to Arm(s): BI 207127 high dose+SOC | Intervention Type: DRUG; Name: Placebo + SOC; Assigned to Arm(s): Placebo + SOC | Intervention Type: DRUG; Name: BI 207127 low dose + SOC; Assigned to Arm(s): BI 207127 low dose + SOC
C: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Filibuvir | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Filibuvir | Arm Label: Arm C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Filibuvir; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Filibuvir; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm C
D: Arm Label: Arm 1 (Control Arm); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo, Biological: Peginterferon alfa-2a, Drug: Ribavirin | Arm Label: Arm 2 (Boceprevir Arm); Type: EXPERIMENTAL; Interventions: Drug: Boceprevir, Biological: Peginterferon alfa-2a, Drug: Ribavirin | Intervention Type: DRUG; Name: Boceprevir; Assigned to Arm(s): Arm 2 (Boceprevir Arm) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm 1 (Control Arm) | Intervention Type: BIOLOGICAL; Name: Peginterferon alfa-2a; Assigned to Arm(s): Arm 1 (Control Arm), Arm 2 (Boceprevir Arm) | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Arm 1 (Control Arm), Arm 2 (Boceprevir Arm)

Answer: B